Tuesday - July 8, 2025
Study Points to Promising Chemoimmunotherapy Strategy for Aggressive Stage III Non-Small Cell Lung Cancer
June 27, 2025
BOSTON, Massachusetts, June 27 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Study Points to Promising Chemoimmunotherapy Strategy for Aggressive Stage III Non-Small Cell Lung Cancer

*

RESEARCH SUMMARY

Study Title: Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

Publication: J . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products